Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055586 · ClinicalTrials.gov registry record
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 10
- Enrollment target
NCT02055586: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT02055586 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02055586 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic procedures, such as FLT-PET/MRI, may help measure a patient's response earlier during treatment.
Primary Outcome
A sample size of 20 produces a two-sided 95% confidence interval \[0.553, 0.918\] for the Pearson correlation coefficient when the sample correlation is 0.80. Additional analysis for concordance will include Bland-Altman plots and intraclass correlation.
Interventions
- OTHER fluorine F 18 fluorothymidine
- DEVICE positron emission tomography
- DEVICE magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2017-12-27 |
What the finished NCT02055586 record still lists
NCT02055586 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which fluorine F 18 fluorothymidine is the first listed.
NCT02055586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02055586 about?
NCT02055586 is a clinical study titled "FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents". This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic procedures, such as FLT-PET...
What is the current status of trial NCT02055586?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2013-10-22. Estimated completion is 2017-12-27.
What interventions are being tested in trial NCT02055586?
The interventions under investigation include: fluorine F 18 fluorothymidine (OTHER), positron emission tomography (DEVICE), magnetic resonance imaging (DEVICE).
Who is sponsoring clinical trial NCT02055586?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI